Heart rate control with adrenergic blockade: Clinical outcomes in cardiovascular medicine

被引:0
作者
Feldman, David [1 ]
Elton, Terry S. [2 ]
Menachemi, Doron M. [3 ]
Wexler, Randy K. [4 ]
机构
[1] Minneapolis Heart Inst, Heart Failure Transplant & VAD Programs, Minneapolis, MN USA
[2] Ohio State Univ, Coll Pharmacol, Div Pharmacol, Columbus, OH USA
[3] Tel Aviv Univ, Edith Wolfson Med Ctr, Inst Heart, Sch Med,Heart Failure Serv, Tel Aviv, Israel
[4] Ohio State Univ, Dept Clin Family Med, Columbus, OH USA
关键词
adrenergic beta-antagonists; heart failure; hypertension; myocardial infarction;
D O I
暂无
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The sympathetic nervous system is involved in regulating various cardiovascular parameters including heart rate (HR) and HR variability. Aberrant sympathetic nervous system expression may result in elevated HR or decreased HR variability, and both are independent risk factors for development of cardiovascular disease, including heart failure, myocardial infarction, and hypertension. Epidemiologic studies have established that impaired HR control is linked to increased cardiovascular morbidity and mortality. One successful way of decreasing HR and cardiovascular mortality has been by utilizing beta-blockers, because their ability to alter cell signaling at the receptor level has been shown to mitigate the pathogenic effects of sympathetic nervous system hyperactivation. Numerous clinical studies have demonstrated that beta-blocker-mediated HR control improvements are associated with decreased mortality in postinfarct and heart failure patients. Although improved HR control benefits have yet to be established in hypertension, both traditional and vasodilating beta-blockers exert positive HR control effects in this patient population. However, differences exist between traditional and vasodilating beta-blockers; the latter reduce peripheral vascular resistance and exert neutral or positive effects on important metabolic parameters. Clinical evidence suggests that attainment of HR control is an important treatment objective for patients with cardiovascular conditions, and vasodilating beta-blocker efficacy may aid in accomplishing improved outcomes.
引用
收藏
页码:387 / 397
页数:11
相关论文
共 102 条
[1]   Heart rate versus heart rate variability in risk prediction after myocardial infarction [J].
Abildstrom, SZ ;
Jensen, BT ;
Agner, E ;
Torp-Pedersen, C ;
Nyvad, O ;
Wachtell, K ;
Ottesen, MM ;
Kanters, JK .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2003, 14 (02) :168-173
[2]  
Rosei EA, 2007, DRUGS, V67, P1097
[3]   Beta blockers in the management of chronic kidney disease [J].
Bakris, G. L. ;
Hart, P. ;
Ritz, E. .
KIDNEY INTERNATIONAL, 2006, 70 (11) :1905-1913
[4]   Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial [J].
Bakris, GL ;
Fonseca, V ;
Katholi, RE ;
McGill, JB ;
Messerli, FH ;
Phillips, RA ;
Raskin, P ;
Wright, JT ;
Oakes, R ;
Lukas, MA ;
Anderson, KM ;
Bell, DSH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (18) :2227-2236
[5]   Relation of Beta-Blocker-Induced Heart Rate Lowering and Cardioprotection in Hypertension [J].
Bangalore, Sripal ;
Sawhney, Sabrina ;
Messerli, Franz H. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (18) :1482-1489
[6]   Meta-analysis of 94,492 patients with hypertension treated with beta Blockers to determine the risk of new-onset diabetes Mellitus [J].
Bangalore, Sripal ;
Parkar, Sanobar ;
Grossman, Ehud ;
Messerli, Franz H. .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (08) :1254-1262
[7]  
Basu S, 1997, CIRCULATION, V96, P183
[8]  
Bohm M, 2008, J HYPERTENS, V26, P18
[9]   How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis [J].
Bradley, Hazel A. ;
Wiysonge, Charles Shey ;
Volmink, Jimmy A. ;
Mayosi, Bongani M. ;
Opie, Lionel H. .
JOURNAL OF HYPERTENSION, 2006, 24 (11) :2131-2141
[10]  
Camm AJ, 1996, CIRCULATION, V93, P1043